News & Events

  • 1. "HONOURED WITH HONORARY.":
    "PROFESSOR & BRAND AMBASSODOR TO IMA" FROM INDIAN MEDICAL ASSOCIATION-2017.
    2. THE BEST DOCTOR OF INDIA-2013 "
    - MEDGATE TODAY SURVEY.
    3. LIBYAN Medical Council Award 1993
    4. Life Time Health Achievement Award, 2005
    5. Bharatiya Chikistak Ratna Award, 2005
    6. Bharat Jyoti Award, 2008
    7. Bharat Chikistak Jyoti Award, 2008
    8. Hon PhD, CU, Florida, USA-2010
    9. Subarta Award 2012
    10.Subarta Award 2012
    11.AWARDS FROM CHAIRPESON
  • 12. Prof. Panda AS GUEST AT 5TH WORLD DIABETES CONGRESS,LAS VEGAS(USA)

    GLARGINE(LANTUS) A NEW HORIZON ULTRALONG BASAL INSULIN IN TYPE II DIABETES ALONG WITH TRIPLE DRUG.

    AUTHOR:-DR PREMANIDHI PANDA,M.D(MED),HON PHD IN DIABETES(USA),MRCP,FRCP
    Prof. Panda DIABETES CENTRE,INDIA
    WEBSITE URL:www.drpandadiabetes.com

    INTRODUCTION:- Diabetes mellitus, often simply referred to as diabetes—is a group of metabolic diseases in which a person has high blood sugar, either because the body does not produce enough insulin, or because cells do not respond to the insulin that is produced.
    In 2000, according to the World Health Organization, at least 171 million people worldwide suffer from diabetes, or 2.8% of the population. Its incidence is increasing rapidly, and it is estimated that by 2030, this number will almost double. The greatest increase in prevalence is, however, expected to occur in Asia and Africa, where most patients will probably be found by 2030  The increase in incidence of diabetes in developing countries follows the trend of urbanization and lifestyle changes, perhaps most importantly a "Western-style" diet.
    Type II diabetes is a progressive disease . It requires two to three drug combinations produce good effects and less side effects. Type 2 diabetes is a condition of relative or absolute insulin deficiency. consists of an array of dysfunctions characterized by hyperglycemia and resulting from the combination of resistance to insulin action, inadequate insulin secretion, and excessive or inappropriate glucagons secretion. It is with both Micro vascular & macro vascular complications Consequently, insulin replacement becomes a common and essential therapy in these individuals. Insulin therapy in type 2 diabetes can range from a single injection to basal-bolus replacement regimens with multiple daily injections. Insulin glargine is a soluble long-acting insulin analog that is widely used in clinical practice for basal insulin replacement.
    My  study  based on when Oral hypoglycemic drug fails to  reduce the blood sugar level the  Glarigine has got more importance then usual  Mixed Insulin.

    INTENT: Intent of the  study done By  Author from 2012 January to  DECEMBER 2012over a period of  One year   over 500 Cases Type –II  Diabetes  shows tremendous result in  reduction of blood sugar, Maintenance of Blood sugar  very stable as compared to  with   Glargine  Subcutaneously  along with three drug therapy (Glimeperide,Metformin 500mg & Piogliazone /Voglibose  whose Blood sugar has not been controlled who are under Uncontrolled  blood sugar  with Three Oral Hypoglycemic Drugs .It shows good glycemic control Constant  maintenance of HBA1C 5.8  to 6.5 range. Reduction in Lipid Profile Serum Cholesterol ,  Serum  Triglyceride,LDL& VLDL.

    BRIEF DESCRIPTION:- Insulin glargine, marketed by Sanofi-Aventis under the name Lantus, is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours, with a "peakless" profile (according to the insulin glargine package insert). Pharmacokinetic ally, it resembles basal insulin secretion of non-diabetic pancreatic beta cells. Sometimes, combinationGlimeperide,Metformin&Pioglitazone/Voglibose with Uncontrolled Diabetes.There is requirement of Insulin to control blood sugar.In comparison giving two or three times I choose Use of Glarigine
    Insulin single dose with 18-26hrs activity found to be more effective.That too Indians are afraid of Taking Insulin.
    In my study I have taken in my convenient dose in sliding scale not 0.5units/Kg body weight.
    <150 Nil
    150-170 2Units
    170-190 4Units
    190-210 6Units SO ON
    In my study I have never found any hypoglycemia except one who has taken small diet than Usual diet. There was tremendous result in with blood sugar,HBA1C,Lipid Profile.

    IN MY STUDY:-When I have used three drugs regimen Glimiperide ½+Metformin+Pioglitazone or Voglibose when FBS remain within 140-200 & 2hr PPBS within 160-280.I started in addition Glarigin
    After which there was tremendous decrease in blood sugar in my own Sliding scale rather than Usual glarigine research dose 0.5Units/Kg Body Weight. In my study Over 500 cases given for period of one year.FBS remain 80-116mg/dl.2Hr PPBS 100-160mg/dl.HBA1C remain 5.6to6.4.Cholesterol,Triglyceride remain normal although with anti cholesterol like Atorvastatin or rosevastatin along with Finofibrate given to the patient with dyslipedimia.
    Although Common side effects include pain, redness, swelling or itching at the injection site. But In my study I have never got anysideeffects.Only one case I found Morning hypoglycemia.
    CONCLUSION:-
    Use of insulin glargine(LANTUS) by giving subcutaneously compared with Without Lantus with three drugs to be continued as before is associated with less nocturnal hypoglycemia and lower post-dinner glucose levels. These data are consistent with peak less and longer duration of action of insulin glargine compared without Lantus . Achievement of acceptable average glucose control requires titration of the insulin dose to an FBG target 110mg/dl. These data support use of insulin glargine (LANTUS)in insulin combination regimens in type 2 diabetes Who those are not controlled with Thee drug Regimen. Patients with shorter duration T2DM better achieved target A1C levels. A single subcutaneous injection of glargine at a dose as per my sliding scale can acutely reduce glucose, HBA1C, and LIPID PROFILE levels for 24 h in obese insulin-resistant type 2 diabetic individuals. Glargine lowers blood glucose by mainly inhibiting EGP with limited effects on stimulating glucose disposal. Large doses of glargine have minimal effects on glucose flux and retain a relatively hepatospecific action in type 2 diabetes. Numerous studies have investigated the clinical efficacy of insulin glargine in both type 1 and type 2 diabetes. Glargine has been found to lower A1C, provide effective basal insulin replacement, and reduce the risk of hypoglycemia.
    References:-
    1.
    1. Riddle MC,
    2. Rosenstock J,
    3. Gerich J
    Insulin Glargine 4002 Study Investigators. The treat to target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients Diabetes Care 2003; 26: 3080–3086
    4. Janka HU,
    5. Plewe G,
    6. Riddle MC,
    7. Kliebe-Frisch C,
    8. Schweitzer MA,
    9. Yki-Järvinen H
    2.: Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005; 28: 254–259
    10. Fritsche A,
    11. Schweitzer MA,
    12. Häring HU
    3.: Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003; 138: 952–959
    13. Porcellati F,
    14. Rossetti P,
    15. Busciantella NR,
    16. Marzotti S,
    17. Lucidi P,
    18. Luzio S,
    19. Owens DR,
    20. Bolli GB,
    21. Fanelli CG
    4.: Comparison of pharmacokinetics and dynamics of the long acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind randomized crossover study. Diabetes Care 2007; 30: 2447–2452
    22. Lepore M,
    23. Pampanelli S,
    24. Fanelli C,
    25. Porcellati F,
    26. Bartocci L,
    27. Di Vincenzo A,
    28. Cordoni C,
    29. Costa E,
    30. Brunetti P,
    31. Bolli GB
    5.: Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142–2148
    5:-
    32. Luzio S,
    33. Dunseath G,
    34. Peter R,
    35. Pauvaday V,
    36. Owens DR
    6:-: Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes. Diabetologia 2006; 49: 1163–1168
    37. Hompesch M,
    38. Ocheltree SM,
    39. Wondmagegnehu ET,
    40. Morrow LA,
    41. Kollmeier AP,
    42. Campaigne BN,
    43. Jacober SJ
    7:-: Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes. Curr Med Res Opin 2009; 25: 2679–2687

    44. Klein O,
    45. Lynge J,
    46. Endahl L,
    47. Damholt B,
    48. Nosek L,
    49. Heise T
    8:-: Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab 2007; 9: 290–299

    50. Heinemann L,
    51. Ampudia-Blasco FJ
    9:-: Glucose clamps with the Biostator: a critical reappraisal. Horm Metab Res 1994; 26: 579–583
    9:-
    52. Abumrad NN,
    53. Rabin D,
    54. Diamond MP,
    55. Lacy WW
    : Use of a heated superficial hand vein as an alternative site for the measurement of amino acid concentration and for the study of glucose and alanine kinetics in man. Metabolism 1981; 30: 936–940
    10:-
    56. Andres R,
    57. Swerdoff T,
    58. Pozefsky T,
    59. Coleman D
    11:-: Manual feedback technique for the control of blood glucose concentration. In Automation in Analytical Chemistry. Skeggs LT Jr Ed. New York, Mediad, 1966, p. 486–491

    60. Wall JS,
    61. Steele R,
    62. De Bodo RC,
    63. Altszuler N
    12:-: Effect of insulin on utilization and production of circulating glucose. Am J Physiol 1957; 189: 43–50
    64. Kuerzel GU,
    65. Shukla U,
    66. Scholtz HE,
    67. Pretorius SG,
    68. Wessels DH,
    69. Venter C,
    70. Potgieter MA,
    71. Lang AM,
    72. Koose T,
    73. Bernhardt E
    13:-: Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Curr Med Res Opin 2003; 19: 34–40
    14:-Glarigine Wikipedia
    Biography

    DR PREMANIDHI PANDA,M.D(MED),HON PhD IN DIABETES,MRCP,FRCP has completed his M.B.B.S at the age of 24 years from Berhampur University, India and postdoctoral studies,M.D(MED) from UTKALUniversity School of Medicine. He is the director of Prof. Panda DIABETES INSTITUTE,INDIA, a premier DIABETES HOSPITAL CUM RESEARCH CENTRE,INDIA.He has worked in TISCO HOSPITAL,INDIA,BENGHAZI MEDICAL(LIBYA),MEDWIN HOSPITAL With Repute.He has been awarded as “INDIA’s BEST DOCTOR AWARD:-2013(DIABETES)” BY MEDGATE TODAY SURVEY.He Has been Awarded MRCP,FRCP BY ROYAL COLLEGE OF PHYSICIAN AND SURGEON. He has published more than 20 papers in reputed journals and serving as Director of Prof. Panda DIABETES INSTITUTE,INDIA. He has been awarded several National & International awards contribution in diabetes.